GlassScriptPhysician profile
Christopher C Mallozzi
NPI 1336507896
$4,655.76
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $739 · 2022: $2,130 · 2023: $1,652 · 2024: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,786.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,242.63 | 2021-2024 | Apretude, Cabenuva, Dovato |
| Novo Nordisk INC | $574.99 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $548.75 | 2022-2023 | |
| Janssen Biotech, INC. | $361.79 | 2022-2023 | Symtuza |
| Abbvie INC. | $338.84 | 2021-2023 | |
| Amgen INC. | $254.02 | 2021-2023 | Otezla, Repatha |
| Theratechnologies INC. | $228.06 | 2021-2024 | Trogarzo, Egrifta |
| Lilly USA, LLC | $164.24 | 2022-2023 | Mounjaro |
| Glaxosmithkline, LLC. | $152.74 | 2021-2023 | Trelegy Ellipta |
| Antares Pharma, INC. | $117.26 | 2022-2023 | Tlando, Nocdurna, Xyosted |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.57 | 2021-2023 | Xifaxan |
| Emd Serono, INC. | $71.80 | 2021-2023 | Serostim |
| Otsuka America Pharmaceutical, INC. | $67.55 | 2022-2023 | Abilify Maintena, Rexulti |
| Pfizer INC. | $67.21 | 2022-2023 | |
| Halozyme INC | $65.83 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $59.75 | 2023-2024 | Delstrigo, Pifeltro, Dificid |
| Esperion Therapeutics, INC. | $46.26 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.73 | 2023 | |
| Hologic Sales and Service, LLC | $25.24 | 2024 | Aptima, Thinprep 2000 Processor |
| Clarus Therapeutics INC. | $20.99 | 2021 | |
| Dexcom, INC. | $18.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.80 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.25 | 2022 | |
| Tolmar, INC. | $16.03 | 2023 | |
| Sanofi-Aventis U.S. LLC | $15.80 | 2021 | |
| Amarin Pharma, INC. | $14.64 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.67 | 2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.25 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mallozzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.